Advanced ovarian cancer - Pipeline Insight, 2024

This “Advanced ovarian cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced ovarian cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Advanced ovarian cancer Understanding

Advanced ovarian cancer: Overview

Advanced ovarian cancer means that the cancer has spread outside the ovary. It may have spread within the pelvis or abdomen, or further away to other parts of the body such as the lungs. Some women have advanced ovarian cancer when they are first diagnosed, and treatment can cure their cancer. This depends on several factors, including the exact stage of the cancer. Chemotherapy, surgery and targeted cancer drugs are all treatments for advanced ovarian cancer. Some women may have radiotherapy. Targeted cancer drugs can help the body to control the growth of cancer cells. Occasionally doctors suggest radiotherapy for advanced ovarian cancer. Radiotherapy can shrink tumours and reduce symptoms.

Advanced ovarian cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced ovarian cancer pipeline landscape is provided which includes the disease overview and Advanced ovarian cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced ovarian cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced ovarian cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Advanced ovarian cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced ovarian cancer.

Advanced ovarian cancer Emerging Drugs Chapters

This segment of the Advanced ovarian cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Advanced ovarian cancer Emerging Drugs

Oregovomab: Onco QuestOregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapyregimen.

Stenoparib: Allarity Therapeutics Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.

DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2).

Advanced ovarian cancer: Therapeutic Assessment

This segment of the report provides insights about the different Advanced ovarian cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Advanced ovarian cancer

There are approx. 50+ key companies which are developing the therapies for Advanced ovarian cancer. The companies which have their Advanced ovarian cancer drug candidates in the most advanced stage, i.e. phase III include, OncoQuest.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Advanced ovarian cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced ovarian cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced ovarian cancer drugs.

Advanced ovarian cancer Report Insights

• Advanced ovarian cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Advanced ovarian cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Advanced ovarian cancer drugs?
• How many Advanced ovarian cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced ovarian cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Advanced ovarian cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Advanced ovarian cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• OncoQuest
• Allarity Therapeutics
• AstraZeneca
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Ellipses Pharma
• Merck KGaA
• Pfizer
• Jiangsu HengRui Medicine Co., Ltd.
• Puma Biotechnology, Inc.
• Bayer
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Daiichi Sankyo, Inc.
• Astellas Pharma Inc

Key Products

• Oregovomab
• Stenoparib
• Durvalumab
• SC10914
• DP303c
• EP0057
• Avelumab
• Talazoparib
• Apatinib
• Neratinib
• BAY1895344
• TQ-B3525
• DS-6000a
• Enzalutamide

This product will be delivered within 1-3 business days.